Gorman Ingmar, Nielson Elizabeth M, Molinar Aja, Cassidy Ksenia, Sabbagh Jonathan
MAPS Public Benefit Corp, Santa Cruz, CA, United States.
Fluence, Woodstock, NY, United States.
Front Psychol. 2021 Mar 15;12:645246. doi: 10.3389/fpsyg.2021.645246. eCollection 2021.
Psychedelic Harm Reduction and Integration (PHRI) is a transtheoretical and transdiagnostic clinical approach to working with patients who are using or considering using psychedelics in any context. The ongoing discussion of psychedelics in academic research and mainstream media, coupled with recent law enforcement deprioritization of psychedelics and compassionate use approvals for psychedelic-assisted therapy, make this model exceedingly timely. Given the prevalence of psychedelic use, the therapeutic potential of psychedelics, and the unique cultural and historical context in which psychedelics are placed, it is important that mental health providers have an understanding of the unique motivations, experiences, and needs of people who use them. PHRI incorporates elements of harm reduction psychotherapy and psychedelic-assisted psychotherapy, and can be applied in both brief and ongoing psychotherapy interactions. PHRI represents a shift away from assessment limited to untoward outcomes of psychedelic use and abstinence-based addiction treatment paradigms and toward a stance of compassionate, destigmatizing acceptance of patients' choices. Considerations for assessment, preparation, and working with difficult experiences are presented.
迷幻药危害减少与整合(PHRI)是一种跨理论和跨诊断的临床方法,用于治疗在任何情况下使用或考虑使用迷幻药的患者。学术研究和主流媒体对迷幻药的持续讨论,再加上最近执法部门对迷幻药的不再优先处理以及迷幻药辅助疗法的同情使用批准,使得这种模式极其及时。鉴于迷幻药使用的普遍性、迷幻药的治疗潜力以及迷幻药所处的独特文化和历史背景,心理健康提供者了解使用迷幻药的人群的独特动机、经历和需求非常重要。PHRI融合了危害减少心理治疗和迷幻药辅助心理治疗的元素,可应用于短期和持续的心理治疗互动中。PHRI代表了一种转变,从仅限于迷幻药使用不良后果的评估和基于禁欲的成瘾治疗范式,转向对患者选择持同情、消除污名化的接受态度。文中还介绍了评估、准备以及应对困难经历的注意事项。